RxDoctor Payments Data

Adam Smith, MD

Family Medicine · Allen, TXNPI 1306899521

Payments from drug & device makers

$407in general payments, 2019–2025

Across 10 payments — averaging $40.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex Medical Incorporated$126
  • Astellas Pharma US Inc$100
  • Currax Pharmaceuticals LLC$50
  • Concordia Pharmaceuticals Inc.$39
  • Supernus Pharmaceuticals, Inc.$36
  • GSK$23
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$25763%
  • Education$15037%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$59,879
Medicare patients
186
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$54,640
JardianceEmpagliflozin23$34,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$32,967
EliquisApixaban22$22,364
MounjaroTirzepatide14$20,810
XareltoRivaroxaban12$10,562
Albuterol Sulfate HfaAlbuterol Sulfate47$1,676
Fluticasone Propionate68$1,450
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,221
Lisinopril147$1,193
Gabapentin79$1,191
Amlodipine Besylate148$1,174
Olmesartan Medoxomil42$1,165
Atorvastatin Calcium135$1,087
Levothyroxine Sodium110$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$23$32,96725 claims
AbbVieSynthroid$14$91814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →